Immunoglobulin Patents (Class 536/23.53)
  • RSV G PROTEIN SPECIFIC ANTIBODIES
    Publication number: 20150004155
    Abstract: The disclosure relates to human isolated, synthetic or recombinant antibodies or functional parts thereof, specific for the RSV G protein. Antibodies specific for the RSV G protein are particularly suitable for counteracting RSV and symptoms, such as inflammation, resulting from an RSV infection. The disclosure further relates to the use of such RSV G-specific antibodies for diagnosis of an RSV infection and as a medicament and/or prophylactic agent for, at least in part, treating or alleviating symptoms of a Respiratory Syncytial Virus infection and/or a Respiratory Syncytial Virus related disorder.
    Type: Application
    Filed: November 16, 2012
    Publication date: January 1, 2015
    Applicant: AIMM THERAPEUTICS B.V.
    Inventors: Tim Beaumont, Etsuko Yasuda
  • Highly-functional mutant of humanized anti-EGFR antibody variable region
    Patent number: 8921525
    Abstract: [Problem] Disclosed is an antibody that exhibits excellent cytotoxicity and cell growth inhibition and that is based on an anti-human epithelial cell growth factor receptor (1) (Her1) antibody (528). Further disclosed is a method for producing same, and the like. [Solution] The mutant of an H chain humanized variable region (5H) or an L chain humanized variable region (5L) of the anti-human epithelial cell growth factor receptor (1) (Her1) antibody (528) is the aforementioned antibody characterized by having one to a plurality (for example: 1 to 5, or 1 to 3) of amino acid mutations within CDR2. Further disclosed are antibody molecules containing said region, a nucleic acid molecule coding for these polypeptides, a method for producing said antibody molecules, and the like.
    Type: Grant
    Filed: November 11, 2010
    Date of Patent: December 30, 2014
    Assignee: Tohoku University
    Inventors: Izumi Kumagai, Takeshi Nakanishi, Ryutaro Asano, Mitsuo Umetsu
  • Anti-VEGF antibodies
    Patent number: 8921537
    Abstract: The invention herein provides isolated antibodies that bind to VEGF. The invention further provides methods of making anti-VEGF antibodies, and polynucleotides encoding anti-VEGF antibodies.
    Type: Grant
    Filed: March 3, 2011
    Date of Patent: December 30, 2014
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Chingwei V. Lee
  • Anti-Bv8 Antibodies and Uses Thereof
    Publication number: 20140377860
    Abstract: The present invention concerns antibodies to Bv8 and the uses of same.
    Type: Application
    Filed: May 29, 2014
    Publication date: December 25, 2014
    Inventors: Xiumin Wu, Yan Wu, Lanlan Yu, Napoleone Ferrara, Wei-Ching Liang, Yu-Ju G. Meng, Janet Tien
  • Dual Variable Domain Immunoglobulin and Uses Thereof
    Publication number: 20140377858
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.
    Type: Application
    Filed: May 29, 2014
    Publication date: December 25, 2014
    Applicant: AbbVie Inc.
    Inventors: Chengbin WU, Tariq GHAYUR, Richard W. DIXON, Jochen G. SALFELD
  • ANTI-HER3 ANTIBODIES AND USES THEREOF
    Publication number: 20140377272
    Abstract: The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: September 8, 2014
    Publication date: December 25, 2014
    Applicant: ROCHE GLYCART AG
    Inventors: Birgit Bossenmaier, Nikolaos Dimoudis, Thomas Friess, Guy Georges, Irene Kolm, Hans-Willi Krell, Valeria Lifke, Ekkehard Moessner
  • HUMANIZED ANTI-CD134 (OX40) ANTIBODIES AND USES THEREOF
    Publication number: 20140377284
    Abstract: The invention provides antibodies that specifically bind to human CD134. Anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Humanized anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.
    Type: Application
    Filed: March 20, 2014
    Publication date: December 25, 2014
    Applicants: JANSSEN PHARMACEUTICALS, INC., BIOCEROX PRODUCTS B.V.
    Inventors: Petrus Johannes SIMONS, Louis BOON, Jinquan LUO, Randall BREZSKI, Monica GOLDBERG
  • FC VARIANTS WITH REDUCED EFFECTOR FUNCTIONS
    Publication number: 20140378663
    Abstract: A method for producing a variant of a parent polypeptide including a Fc region, which variant exhibits reduced binding to the protein C1q and to at least one receptor Fcg? R as compared to the parent polypeptide.
    Type: Application
    Filed: June 25, 2012
    Publication date: December 25, 2014
    Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DE BIOTECHNOLOGIES
    Inventors: Alexandre Fontayne, Sylvie Jorieux, Celine Monnet-Mars, Philippe Mondon, Abdelhakim Kharrat, Khalil Bouayadi
  • NON-SIALYLATED ANTI-INFLAMMATORY POLYPEPTIDES
    Publication number: 20140377280
    Abstract: This invention concerns anti-inflammatory agents, compositions, and methods for treating inflammatory disorders.
    Type: Application
    Filed: December 10, 2012
    Publication date: December 25, 2014
    Inventors: Jeffrey V. Ravetch, Andrew Pincetic
  • MOLECULES WITH EXTENDED HALF-LIVES, COMPOSITIONS AND USES THEREOF
    Publication number: 20140377181
    Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
    Type: Application
    Filed: June 20, 2014
    Publication date: December 25, 2014
    Applicants: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, MEDIMMUNE, LLC
    Inventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward Ober
  • NATURALLY OCCURRING AUTOANTIBODIES AGAINST ALPHA-SYNUCLEIN THAT INHIBIT THE AGGREGATION AND CYTOTOXICITY OF ALPHA-SYNUCLEIN
    Publication number: 20140377271
    Abstract: The present invention refers to human antibodies which are directed against ?-Synuclein (?-Syn) and their use in medicine and diagnosis.
    Type: Application
    Filed: April 18, 2014
    Publication date: December 25, 2014
    Applicant: Dr. Rentschler Holding GmbH & Co. KG
    Inventors: Richard DODEL, Michael BACHER, Daniela BESONG AGBO, Sascha HAGEMANN, Monika BALZER-GELDSETZER, Bernd REHBERGER, Renee WEBER
  • PROTEIN COMPLEX, BISPECIFIC ANTIBODY INCLUDING THE PROTEIN COMPLEX, AND METHOD OF PREPARATION THEREOF
    Publication number: 20140378664
    Abstract: A protein complex comprising a first polypeptide comprising a first antigen-binding region; a second polypeptide comprising a second antigen-binding region; and a linker connecting the first polypeptide and the second polypeptide, wherein the first antigen-binding region is a single stranded polypeptide comprising a first light chain antigen-binding region and a first heavy chain antigen-binding region, the second antigen-binding region is a single stranded polypeptide comprising a second light chain antigen-binding region and a second heavy chain antigen-binding region, and the linker connects the C-terminal of the first polypeptide and the N-terminal of the second polypeptide, and comprises a tag including a cleavable amino acid sequence at one terminal or both terminals of the linker; as well as a bispecific antibody derived from the protein complex, and related compositions and methods.
    Type: Application
    Filed: June 25, 2014
    Publication date: December 25, 2014
    Inventors: Hye young SUH, Jae II Lee, Su-Jeong Hwang
  • FC VARIANTS
    Publication number: 20140377253
    Abstract: The present disclosure relates to polypeptide variants having modified Fc domains with altered affinity to Fc receptors.
    Type: Application
    Filed: March 14, 2014
    Publication date: December 25, 2014
    Applicant: ABBVIE BIOTHERAPEUTICS INC.
    Inventors: Fiona A. HARDING, Paul R. HINTON, Mengli XIONG, Olivia Jennifer RAZO, Shiming YE
  • OPTIMIZED ANTIBODY VARIABLE REGIONS
    Publication number: 20140377270
    Abstract: The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.
    Type: Application
    Filed: March 12, 2014
    Publication date: December 25, 2014
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • OPTIMIZED FC VARIANTS AND METHODS FOR THEIR GENERATION
    Publication number: 20140377256
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Application
    Filed: May 23, 2014
    Publication date: December 25, 2014
    Applicant: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John R. Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEM
    Publication number: 20140377279
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Application
    Filed: September 13, 2013
    Publication date: December 25, 2014
    Applicant: MedImmune Limited
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • ANTI-HER3 ANTIBODIES AND USES THEREOF
    Publication number: 20140377273
    Abstract: The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: September 8, 2014
    Publication date: December 25, 2014
    Applicant: ROCHE GLYCART AG
    Inventors: Birgit Bossenmaier, Nikolaos Dimoudis, Thomas Friess, Guy Georges, Irene Kolm, Hans-Willi Krell, Valeria Lifke, Ekkehard Moessner
  • ANTI-KDR ANTIBODIES AND METHODS OF USE
    Publication number: 20140377282
    Abstract: The present invention provides anti-KDR monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of a variety of cancers, rheumatoid arthritis, diabetic retinopathy and other diseases associated with aberrant VEGF or KDR expression and/or activity.
    Type: Application
    Filed: November 1, 2012
    Publication date: December 25, 2014
    Applicant: APEXIGEN, INC.
    Inventors: Yaohuang Ke, Sum Wai Pierre Lee, Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • ANTI-CXCR3 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20140377806
    Abstract: The present disclosure provides anti-CXCR3 antibodies and methods of using the antibodies to diagnose and/or treat CXCR3-associated disorders such as diabetes mellitus type I (T1D), particularly new-onset T1D. In certain embodiments, disclosed herein are CXCR3 neutralizing antibodies.
    Type: Application
    Filed: September 8, 2014
    Publication date: December 25, 2014
    Inventors: Michele Youd, Jennifer Tedstone, Tracey Lodie, Karen B. Carter, Timothy D. Connors, Jason Robert Pinckney, Elizabeth Masterjohn, Ruiyin Chu
  • 4-1BB BINDING MOLECULES
    Publication number: 20140377255
    Abstract: The present disclosure provides isolated binding molecules that bind to human 4-1BB, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.
    Type: Application
    Filed: May 13, 2014
    Publication date: December 25, 2014
    Applicant: PFIZER INC
    Inventors: Bianca Ahrens, Sangita M. Baxi, Timothy Scott Fisher, Richard Michael Jerome, Kathrin Ladetzki-Baehs, Theodore Oliphant, Leslie Lynne Sharp, Michael Tesar, Libbey Anne Yates, Moritz Zulley
  • Antigen binding proteins to oncostatin M (OSM)
    Patent number: 8916695
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanizing antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: December 23, 2014
    Assignee: Glaxo Group Limited
    Inventors: Gary Peter Bembridge, Chun-Wa Chung, Maria Feeney, Susannah Karen Ford, Ian Kirby, Ruth McAdam
  • ANTIGEN-BINDING MOLECULE HAVING REGULATED CONJUGATION BETWEEN HEAVY-CHAIN AND LIGHT-CHAIN
    Publication number: 20140370020
    Abstract: It was found that association between CH1 and CL can be suppressed by substituting amino acids that exist on the interface between CH 1 and CL with electrically-charged amino acids, and that formation of heterogeneous molecules is enabled more efficiently than by introducing knobs into holes mutations into CH3 domain.
    Type: Application
    Filed: October 31, 2012
    Publication date: December 18, 2014
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Taichi Kuramochi, Meiri Kawazoe, Naoka Hironiwa, Tomoyuki Igawa
  • ANTIBODIES CROSS-REACTIVE TO HUMAN AND MOUSE c-Met AND USES THEREOF
    Publication number: 20140370022
    Abstract: The antibody of the invention has high specificity to human c-Met and is cross-reactive to mouse c-Met. The antibody or its antigen-binding fragment of the invention is capable of specifically binding to human c-Met as well as mouse c-Met, more accurate preclinical results can be confirmed in the efficacy evaluation using mouse tumor models. The antibody of the invention inhibits the growth of cancer cells derived from various cancers by a considerable binding affinity to c-Met and the suppression of c-Met function therefrom, inhibits the phosphorylation of c-Met and downstream signaling molecules to suppress c-Met signaling, and inhibits neovascularization, thereby being very efficient in the prevention and treatment of cancers.
    Type: Application
    Filed: February 20, 2014
    Publication date: December 18, 2014
    Applicant: Samsung Life Public Welfare Foundation
    Inventors: Seok-Hyung KIM, Do-Hyun NAM, Hyun-Kyu PARK, Kyeung Min JOO, Nam Kyung LEE
  • Anti-Alpha Synuclein Binding Molecules
    Publication number: 20140369940
    Abstract: Provided are anti-human ?-synuclein-specific binding molecules, e.g., antibodies or antigen-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human ?-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human ?-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.
    Type: Application
    Filed: June 22, 2012
    Publication date: December 18, 2014
    Applicants: University of Zurich, Biogen IDEC International Neuroscience GmbH
    Inventors: Andreas Weihofen, Jan Grimm, Cristoph Hock, Roger Nitsch, Lihe Su, Paul Weinreb
  • BISPECIFIC ANTIBODIES SPECIFIC FOR FAP AND DR5, ANTIBODIES SPECIFIC FOR DR5 AND METHODS OF USE
    Publication number: 20140370019
    Abstract: The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: April 1, 2014
    Publication date: December 18, 2014
    Applicant: ROCHE GLYCART AG
    Inventors: Peter Bruenker, Sherif Daouti, Ningping Feng, Claudia Ferrara Koller, Guy Georges, Sandra Grau-Richards, Ralf Hosse, Christian Klein, Maximiliane Koenig, Joerg Moelleken, Ekkehard Moessner, Huifeng Niu, Kathryn E. Packman, Valeria Runza, Stefan Seeber, Pablo Umana, Inja Waldhauer, Huisheng Wang, Barbara Weiser
  • NOVEL HETERODIMERIC PROTEINS
    Publication number: 20140370013
    Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.
    Type: Application
    Filed: January 14, 2014
    Publication date: December 18, 2014
    Applicant: Xencor, Inc.
    Inventors: John R. Desjarlais, Gregory L. Moore, Rumana Rashid, Matthew J. Bernett
  • RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS
    Publication number: 20140369926
    Abstract: The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.
    Type: Application
    Filed: June 19, 2014
    Publication date: December 18, 2014
    Inventors: J. Andrew BRISTOL, Judith A. KANTOR
  • Poly-N-acetyl glucosamine (PNAG/dPNAG)-binding peptides and methods of use thereof
    Patent number: 8912314
    Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.
    Type: Grant
    Filed: January 7, 2013
    Date of Patent: December 16, 2014
    Assignees: The Brigham and Woman's Hospital, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Gerald B. Pier, Casie Anne Kelly-Quintos, Lisa Cavacini, Marshall R. Posner
  • Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
    Publication number: 20140363433
    Abstract: In one aspect, the invention provides a method of making a bioactive peptide-bearing antibody, or fragment thereof, comprising (a) engrafting the amino acid sequence of at least one bioactive peptide of interest into (i) at least one of CDR-H1, CDR-H2 or CDR-H3 of a heavy chain variable region comprising one or more chicken framework regions and/or (ii) at least one of CDR-L1, CDR-L2 or CDR-L3 of the light chain variable region comprising one or more chicken framework regions, and (b) determining whether the antibody has substantially the same biological activity as the bioactive peptide.
    Type: Application
    Filed: March 12, 2014
    Publication date: December 11, 2014
    Inventors: W. Jason Cummings, Patrick Gray, Larry Tjoelker, Munehisa Yabuki
  • BINDING MOLECULES SPECIFIC FOR HER3 AND USES THEREOF
    Publication number: 20140363429
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.
    Type: Application
    Filed: November 20, 2012
    Publication date: December 11, 2014
    Applicant: MedImmune LLC
    Inventors: Partha S. Chowdhury, David Tice, Zhan Xiao, Philipp Steiner, Krista Kinneer, Marlon Rebelatto
  • BINDING AGENTS TO INTRACELLULAR TARGET MOLECULES
    Publication number: 20140363434
    Abstract: The application provides polypeptides comprising or essentially consisting of at least one Alphabody, wherein said Alphabody is capable of internalization into a cell and specifically binds to an intracellular target molecule. The application further provides nucleic acids encoding such polypeptides; methods for preparing such polypeptides; host cells expressing or capable of expressing such polypeptides; compositions, and in particular to pharmaceutical compositions, that comprise such polypeptides, nucleic acids and/or host cells; and uses of such polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.
    Type: Application
    Filed: January 4, 2013
    Publication date: December 11, 2014
    Applicant: COMPLIX NV
    Inventors: Ignace Lasters, Mark Vaeck, Johan Desmet, Jürgen Debaveye, Sabrina Deroo, Stefan Loverix
  • METHOD OF TREATING CANCER COMPRISING A VEGF-B ANTAGONIST
    Publication number: 20140363445
    Abstract: The present invention relates generally to the field of cancer therapy and prophylaxis. More particularly, the present invention provides growth factor antagonists which inhibit the growth of cancers including tumors and pre-cancerous tissue. Even more particularly, the present invention is directed to antagonists of vascular endothelial growth factor-B and their use to inhibit the growth of cancer including tumor tissue and pre-cancerous tissue.
    Type: Application
    Filed: August 11, 2014
    Publication date: December 11, 2014
    Applicant: ZENYTH OPERATIONS PTY LTD
    Inventors: Andrew Nash, Felicity Meredith Dunlop, Manuel Baca, Louis Jerry Fabri, Pierre David Scotney
  • Activatable Antibodies that Bind Interleukin-6 Receptor and Methods of Use Thereof
    Publication number: 20140363430
    Abstract: The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to interleukin-6 receptor (IL-6R), and to methods of making and using these anti-IL-6R activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: September 25, 2013
    Publication date: December 11, 2014
    Applicant: CYTOMX THERAPEUTICS, INC.
    Inventors: James William West, Jason Gary Sagert, Daniel Robert Hostetter, Stephen James Moore, Margaret Thy Luu Nguyen, Olga Vasiljeva, Jeanne Grace Flandez
  • NEUREGULIN ANTIBODIES AND USES THEREOF
    Publication number: 20140363438
    Abstract: The invention provides anti-neuregulin1 antibodies and methods of using the antibodies in treating diseases or disorders, such as cancer. In a particular embodiment, the anti-neuregulin1 antibodies bind to both neuregulin1? and neuregulin 1? isoforms.
    Type: Application
    Filed: August 16, 2012
    Publication date: December 11, 2014
    Applicant: Genentech, Inc.
    Inventors: Erica Jackson, Gabriele Schaefer, Yan Wu
  • ANTI-LRP6 ANTIBODIES
    Publication number: 20140363439
    Abstract: The invention provides anti-LRP6 antibodies and methods of using the same. A particular aspect of the invention provides for bispecific anti-LRP6 antibodies that inhibit signaling by multiple Wnt isoforms.
    Type: Application
    Filed: August 22, 2014
    Publication date: December 11, 2014
    Applicant: GENENTECH, INC.
    Inventors: Eric Bourhis, Rick Carano, Andrea Cochran, Mike Costa, Venita DeAlmeida, James Ernst, Yan Gong, Rami Hannoush, Paul Polakis, Bonnee Rubinfeld, Mark Solloway, Yan Wu
  • METHOD OF PROVIDING MONOCLONAL AUTO-ANTIBODIES WITH DESIRED SPECIFICITY
    Publication number: 20140363422
    Abstract: Provided are novel binding molecules of human origin, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize antigens such as native endogenous proteins associated with, e.g., immune response, autoimmune disorders, inflammatory diseases, metabolic disorders, vascular function, neurodegenerative diseases or tumors. More particularly, a human Auto-Immunosome and corresponding monoclonal antibody reservoir are provided. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy of are described.
    Type: Application
    Filed: January 2, 2013
    Publication date: December 11, 2014
    Inventors: Adrian Hayday, Kai Krohn, Annamari Ranki, Part Peterson, Kai Kisand, Edward Stuart, Annalisa MacAgno, Shimobi Onuoha
  • DLL3 MODULATORS AND METHODS OF USE
    Publication number: 20140363887
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: August 22, 2014
    Publication date: December 11, 2014
    Applicant: STEM CENTRX, INC.
    Inventors: ROBERT A. STULL, LAURA SAUNDERS, SCOTT J. DYLLA, ORIT FOORD, DAVID LIU, MICHAEL TORGOV, HUI SHAO
  • Amino acid sequences directed against chemokines and polypeptides comprising the same for the treatment of chemokine-related diseases and disorders
    Patent number: 8906680
    Abstract: The present invention relates to amino acid sequences that are directed against chemokines, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides; to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: December 9, 2014
    Assignee: Ablynx N.V.
    Inventors: Christophe Blanchetot, Michael John Scott Saunders, Johannes Joseph Wilhelmus De Haard
  • Antibodies binding human collagen II
    Patent number: 8906649
    Abstract: The present invention relates to antibodies against human collagen II, polypeptides and polynucleotides encoding human collagen II antibodies or fragments thereof, and methods of making and using the foregoing.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: December 9, 2014
    Assignee: Janssen Biotech, Inc.
    Inventors: John Kehoe, Tatiana Ort, Kristen Picha, Mary Ryan, John Wheeler, Jennifer Lee Gardiner
  • Nucleic acids encoding antibody 137-26 which binds C5 and C5a
    Patent number: 8907072
    Abstract: The invention relates to inhibitors that bind to C5 and C5a, but which do not prevent the activation of C5 and do not prevent formation of or inhibit the activity of C5b. One example of such an inhibitor molecule is the monoclonal antibody designated MAb137-26, which binds to a shared epitope of human C5 and C5a. These inhibitors may be used to inhibit the activity of C5a in treating diseases and conditions mediated by excessive or uncontrolled production of C5a. The inhibitor molecules are also useful for diagnostic detection of the presence/absence or amount of C5 or C5a.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: December 9, 2014
    Assignee: Genentech, Inc.
    Inventors: Michael Fung, Meisheng Lu, William N. C. Sun, Cecily R. Y. Sun
  • HUMAN GROWTH HORMONE RECEPTOR ANTAGONIST ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20140356359
    Abstract: The present invention provides antagonizing antibodies that bind to growth hormone receptor (GHR). The invention further relates to therapeutic methods for use of these antibodies to reduce IGF-1 levels and/or for the treatment and/or prevention of diseases associated with excessive IGF-1, including treatment of acromegaly, gigantism, cancer, diabetic nephropathy, arthritis, and lung inflammation.
    Type: Application
    Filed: December 10, 2012
    Publication date: December 4, 2014
    Inventors: Sara Iva Siebel, Edward Derrick Pascua, Chia-Yang Lin, Javier Fernando Chaparro Riggers
  • NUCLEIC ACID ENCODING ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)
    Publication number: 20140357853
    Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
    Type: Application
    Filed: August 14, 2014
    Publication date: December 4, 2014
    Inventors: Simon Mark Jackson, Nigel Pelham Clinton Walker, Derek Evan Piper, Bei Shan, Wenyan Shen, Joyce Chi Yee Chan, Chadwick Terence King, Randal Robert Ketchem, Christopher Mehlin, Teresa Arazas Carabeo, Qiong Cao
  • ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES
    Publication number: 20140356375
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Application
    Filed: May 22, 2014
    Publication date: December 4, 2014
    Applicant: GENENTECH, INC.
    Inventors: Eric J. Brown, Martine Darwish, John Flygare, Wouter Hazenbos, Byoung Chul Lee, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES
    Publication number: 20140356376
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Application
    Filed: May 30, 2014
    Publication date: December 4, 2014
    Applicant: GENENTECH, INC.
    Inventors: Eric J. Brown, Martine Darwish, John Flygare, Wouter Hazenbos, Byoung Chul Lee, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • NUCLEIC ACID ENCODING ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)
    Publication number: 20140357852
    Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
    Type: Application
    Filed: August 14, 2014
    Publication date: December 4, 2014
    Inventors: Simon Mark Jackson, Nigel Pelham Clinton Walker, Derek Evan Piper, Bei Shan, Wenyan Shen, Joyce Chi Yee Chan, Chadwick Terence King, Randal Robert Ketchem, Christopher Mehlin, Teresa Arazas Carabeo, Qiong Cao
  • VARIANT FC-POLYPEPTIDES WITH ENHANCED BINDING TO THE NEONATAL FC RECEPTOR
    Publication number: 20140356358
    Abstract: Described herein are variant Fc-fragments that contain an insertion within or adjacent to a loop that bind to the neonatal Fc receptor (FcRn) with higher affinity and/or higher binding activity at pH 5-6 and approximately the same or lower affinity at a physiologic pH as compared to a control Fc-fragment, that is, little or no binding activity at a physiologic pH. Also described are variant Fc-polypeptides that comprise these variant Fc-fragments. Further described are methods of making and identifying such Fc-fragments and methods for making and using such Fc-polypeptides.
    Type: Application
    Filed: December 17, 2012
    Publication date: December 4, 2014
    Inventors: Jeonghoon Sun, Seog Joon Han, Susie M. Harris, Randal R Ketchem, Ji Lu, Mark L Michaels, Marc W Retter, Mei-Mei Tsai
  • TARGETED BINDING AGENTS AGAINST B7-H1
    Publication number: 20140356353
    Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.
    Type: Application
    Filed: May 6, 2014
    Publication date: December 4, 2014
    Inventors: CHRISTOPHE QUEVA, MICHELLE MORROW, SCOTT HAMMOND, MARAT ALIMZHANOV, JOHN BABCOCK, IAN Nevin FOLTZ, JASPAL SINGH KANG, LAURA SEKIROV, MELANIE BOYLE, MATTHIEU CHODORGE, ROSS A. STEWARD, KATHLEEN ANN MULGREW
  • THERAPY FOR FILOVIRUS INFECTION
    Publication number: 20140356354
    Abstract: The present invention addresses a need for improved treatments for filovirus infections.
    Type: Application
    Filed: May 30, 2014
    Publication date: December 4, 2014
    Applicants: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY, University of Toronto, Government of the United States
    Inventors: Jonathan R. Lai, Jayne F. Koellhoffer, Julia Frei, Kartik Chandran, Sachdev Sidhu, Gang Chen, John M. Dye, JR., Samantha Zak
  • ANTIBODIES SPECIFIC FOR TROP-2 AND THEIR USES
    Publication number: 20140357844
    Abstract: The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.
    Type: Application
    Filed: August 15, 2014
    Publication date: December 4, 2014
    Inventors: Shu-Hui LIU, Wei-Hsien HO, Pavel STROP, Magdalena Grazyna DORYWALSKA, Arvind RAJPAL, David Louis SHELTON, Thomas-Toan TRAN
  • IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS
    Publication number: 20140356355
    Abstract: The present invention relates to IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation by one or more IL-17 ligands. The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and antibodies that bind thereto. Aspects of the invention also include antibodies that compete for binding with the IL-17RA neutralizing antibodies described herein.
    Type: Application
    Filed: June 13, 2014
    Publication date: December 4, 2014
    Inventors: Joel E. Tocker, Jacques J. Peschon, David Fitzpatrick, James F. Smothers, Christopher Mehlin, Ai Ching Lim